Nicht alkoholische Fettlebererkrankung (NAFLD) – Ursachen, Diagnostik, Therapie

Die nicht alkoholische Fettlebererkrankung (NAFLD) ist die häufigste chronische Lebererkrankung mit steigender Prävalenz und großer sozioökonomischer Bedeutung. Bisher gibt es keine zugelassene medikamentöse Therapie der NAFLD – Gewichtsreduktion und die Therapie der metabolischen Risikofaktoren stehen im Vordergrund. Dieser Beitrag beleuchtet Ursachen, Diagnostik und Therapie der Erkrankungen, die unter dem Begriff NAFLD zusammengefasst werden.

Schlüsselwörter

nicht alkoholische Fettlebererkrankung - nicht alkoholische Steatohepatitis - metabolisches Syndrom

• Literatur

• 1 Weiss J, Rau M, Geier A. Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment. Dtsch Arztebl Int 2014; 111: 447-452
• 2 Roeb E, Steffen HM, Bantel H. et al. [S2k Guideline non-alcoholic fatty liver disease]. Z Gastroenterol 2015; 53: 668-723
• 3 Trepo E, Nahon P, Bontempi G. et al. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology 2014; 59: 2170-2177
• 4 Younossi Z, Tacke F, Arrese M. et al. Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepatology 2018;
• 5 Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231
• 6 Younossi ZM, Stepanova M, Rafiq N. et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011; 53: 1874-1882
• 7 Ekstedt M, Hagstrom H, Nasr P. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547-1554
• 8 Piscaglia F, Svegliati-Baroni G, Barchetti A. et al. Clinical patterns of hepatocellular carcinoma (hcc) in non alcoholic fatty liver disease (NAFLD): A multicenter prospective study. Hepatology 2016; 63: 827-838
• 9 Angulo P, Hui JM, Marchesini G. et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854
• 10 Cassinotto C, Lapuyade B, Mouries A. et al. Non-invasive assessment of liver fibrosis with impulse elastography: comparison of Supersonic Shear Imaging with ARFI and FibroScan(R). J Hepatol 2014; 61: 550-557
• 11 Bedossa P, Poitou C, Veyrie N. et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012; 56: 1751-1759
• 12 Kleiner DE, Brunt EM, Van Natta M. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321
• 13 Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L. et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015; 149: 367-378.e5
• 14 Sanyal AJ, Chalasani N, Kowdley KV. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685
• 15 European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402
• 16 Armstrong MJ, Gaunt P, Aithal GP. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387: 679-690
• 17 Neuschwander-Tetri BA, Loomba R, Sanyal AJ. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385: 956-965
• 18 Ratziu V, Harrison SA, Francque S. et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 2016; 150: 1147-1159.e5
• 19 Friedman SL, Ratziu V, Harrison SA. et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology 2018; 67: 1754-1767
• 20 Loomba R, Lawitz E, Mantry PS. et al. GS-4497, an inhibitor of apoptosis signal-regulating kinase (ASK1), alone or in combination with simtuzumab for the treatment of nonalcoholic steatohepatitis (NASH): a randomized, phase 2 trial. Boston (MA): AASLD Liver Meeting; 2016: Abstract. LB-3
• 21 Lee Y, Doumouras AG, Yu J. et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2018;